Response to alectinib oil-based suspension in anaplastic lymphoma kinase-positive non-small cell lung cancer in a patient unable to swallow: A case report
Restricted accessCase reportFirst published online October, 2019
Response to alectinib oil-based suspension in anaplastic lymphoma kinase-positive non-small cell lung cancer in a patient unable to swallow: A case report
The emergence of oral targeted therapy in the management of non-small cell lung cancer with targetable oncogenes has led to significant improvements in progression-free survival, toxicity profile, and quality of life compared to intravenous chemotherapy. However, patients unable to swallow or with exclusive enteral feeding are left without alternative formulations for these targeted therapies given their availability only in tablet or capsule formulations. We report a case of a woman with metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer who was unable to swallow and was successfully treated with an oil-based alectinib liquid suspension.
SolomonBJMokTKimDW, et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med2014; 371: 2167–2177.
2.
MaemondoMInoueAKobayashiK, et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med2010; 362: 2380–2388.
3.
ShawATKimTMCrinoL, et al.Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol2017; 18: 874–886.
4.
SequistLVYangJCYamamotoN, et al.Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol2013; 31: 3327–3334.
5.
ShawATSolomonB. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res2011; 17: 2081–2086.
6.
PetersSCamidgeDRShawAT, et al.Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med2017; 377: 829–838.
7.
Bosch-BarreraJSaisELorencioC, et al.Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung Cancer2014; 86: 102–104.
8.
KanaiOKimYHNakataniK, et al.Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status. Clin Case Rep2017; 5: 927–930.
9.
SuzumuraTYonesakaKTsukudaH, et al.Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia. BMJ Case Rep2014; 13 March 2014. doi:10.1136/bcr-2013-202705.
10.
TamaiKNagataKOtsukaK, et al.Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status. Respir Investig2013; 51: 46–48.
11.
USP. USP <795> Pharmaceutical compounding – nonsterile preparations. Second supplement to USP 40–NF 35.675–83.
